Glutamate modulators and beyond: A neuroscience revolution in the making.
作者信息
Zarate Carlos A
机构信息
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States.
出版信息
Eur Neuropsychopharmacol. 2022 Jan;54:72-74. doi: 10.1016/j.euroneuro.2021.09.005. Epub 2021 Sep 24.
Abstract
摘要
相似文献
1
Glutamate modulators and beyond: A neuroscience revolution in the making.谷氨酸调节剂及其他：一场正在形成的神经科学革命。
Eur Neuropsychopharmacol. 2022 Jan;54:72-74. doi: 10.1016/j.euroneuro.2021.09.005. Epub 2021 Sep 24.
2
Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.捕捉“天使尘”中的天使：二十年来 NMDA 受体拮抗剂在动物和人类中的转化神经科学研究。
Schizophr Bull. 2012 Sep;38(5):942-9. doi: 10.1093/schbul/sbs075. Epub 2012 Aug 16.
3
Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors.氯胺酮及其主要代谢产物作为阿片受体的变构调节剂。
Mol Pharmacol. 2024 Oct 17;106(5):240-252. doi: 10.1124/molpharm.124.000947.
4
Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators.近期 II 组代谢型谷氨酸受体变构调节剂的合成与表征研究进展。
ACS Chem Neurosci. 2011 Aug 17;2(8):382-93. doi: 10.1021/cn200008d. Epub 2011 Apr 12.
5
Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor.苯基 - 四唑基苯乙酮：代谢型谷氨酸2受体正向变构增强剂的发现
J Med Chem. 2004 Aug 26;47(18):4595-9. doi: 10.1021/jm040088h.
6
Bidirectional variation in glutamate efflux in the medial prefrontal cortex induced by selective positive and negative allosteric mGluR5 modulators.内侧前额叶皮层谷氨酸外排的双向变化由选择性正、负变构 mGluR5 调节剂诱导。
J Neurochem. 2018 Apr;145(2):111-124. doi: 10.1111/jnc.14290. Epub 2018 Feb 12.
7
Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.基于结构的代谢型谷氨酸受体 5 的负变构调节剂的发现。
ACS Chem Biol. 2022 Oct 21;17(10):2744-2752. doi: 10.1021/acschembio.2c00234. Epub 2022 Sep 23.
8
Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators.代谢型谷氨酸受体亚型4（mGluR4）的正变构调节剂：第一部分。吡唑并[3,4-d]嘧啶作为新型mGluR4正变构调节剂的发现。
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5626-30. doi: 10.1016/j.bmcl.2008.08.087. Epub 2008 Aug 29.
9
Differential Pharmacology and Binding of mGlu Receptor Allosteric Modulators.代谢型谷氨酸受体变构调节剂的差异药理学和结合。
Mol Pharmacol. 2018 May;93(5):526-540. doi: 10.1124/mol.117.110114. Epub 2018 Mar 15.
10
Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.代谢型谷氨酸受体2正变构调节剂的药理学和分子特征重印版
Neuropharmacology. 2017 Mar 15;115:115-127. doi: 10.1016/j.neuropharm.2016.08.040. Epub 2017 Feb 16.
引用本文的文献
1
cAMP-dependent protein kinase signaling is required for ()-hydroxynorketamine to potentiate hippocampal glutamatergic transmission.环磷腺苷依赖性蛋白激酶信号通路对于 (-)-羟基去甲氯胺增强海马谷氨酸能传递是必需的。
J Neurophysiol. 2024 Jan 1;131(1):64-74. doi: 10.1152/jn.00326.2023. Epub 2023 Dec 5.
2
(2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity.(2R,6R)-羟基去甲氯胺迅速增强光刺激下的 Schaffer 侧枝突触活动。
Neuropharmacology. 2022 Aug 15;214:109153. doi: 10.1016/j.neuropharm.2022.109153. Epub 2022 May 31.
本文引用的文献
1
Brain circuitry in major depressive disorder: The critical role of ventral anterior cingulate cortex.
Eur Neuropsychopharmacol. 2021 Oct;51:134-137. doi: 10.1016/j.euroneuro.2021.07.001. Epub 2021 Aug 11.
2
Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.调整神经兴奋/抑制以实现针对治疗抵抗性抑郁症的个体化氯胺酮治疗。
Transl Psychiatry. 2021 May 29;11(1):335. doi: 10.1038/s41398-021-01442-3.
3
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.新型谷氨酸能调节剂治疗心境障碍的研究进展
CNS Drugs. 2021 May;35(5):527-543. doi: 10.1007/s40263-021-00816-x. Epub 2021 Apr 26.
4
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.氯胺酮对映异构体的药理学和行为学差异：对滥用倾向的影响。
Mol Psychiatry. 2021 Nov;26(11):6704-6722. doi: 10.1038/s41380-021-01093-2. Epub 2021 Apr 15.
5
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.总结氯胺酮和艾司氯胺酮治疗难治性抑郁症的证据：现有证据和实施情况的国际专家意见。
Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17.
6
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.氯胺酮和血清素能致幻剂：快速作用抗抑郁药作用的共同机制。
Int J Neuropsychopharmacol. 2021 Jan 20;24(1):8-21. doi: 10.1093/ijnp/pyaa087.
7
Neurobiological biomarkers of response to ketamine.氯胺酮反应的神经生物学生物标志物。
Adv Pharmacol. 2020;89:195-235. doi: 10.1016/bs.apha.2020.05.003. Epub 2020 Jun 18.
8
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.快速作用抗抑郁药的分子药理学和神经生物学。
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:213-236. doi: 10.1146/annurev-pharmtox-010617-052811. Epub 2018 Oct 8.
9
CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?中枢神经系统（CNS）靶点鉴定与验证：避免死亡之谷或盲目乐观？
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:171-187. doi: 10.1146/annurev-pharmtox-010716-104624. Epub 2016 Aug 15.
10
Glutamate-based antidepressants: 20 years on.基于谷氨酸的抗抑郁药：20 年的发展历程。
Trends Pharmacol Sci. 2009 Nov;30(11):563-9. doi: 10.1016/j.tips.2009.09.002.
Zotero 插件